BARICITINIB

Open Access
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
Charles Peterfy, Julie DiCarlo, Paul Emery, Mark C. Genovese, Edward C. Keystone, Peter C. Taylor, Doug E. Schlichting, Scott D. Beattie, Monica Luchi and William Macias

The Journal of Rheumatology August 1 2019, 46 (8) 887-895; DOI: https://doi.org/10.3899/jrheum.171469
Open Access
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
Josef S. Smolen, Mark C. Genovese, Tsutomu Takeuchi, David L. Hyslop, William L. Macias, Terence Rooney, Lei Chen, Christina L. Dickson, Jennifer Riddle Camp, Tracy E. Cardillo, Taeko Ishii and Kevin L. Winthrop

The Journal of Rheumatology January 1 2019, 46 (1) 7-18; DOI: https://doi.org/10.3899/jrheum.171361
Open Access
Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis
Edward C. Keystone, Mark C. Genovese, Douglas E. Schlichting, Inmaculada de la Torre, Scott D. Beattie, Terence P. Rooney and Peter C. Taylor

The Journal of Rheumatology January 1 2018, 45 (1) 14-21; DOI: https://doi.org/10.3899/jrheum.161161
Open Access
Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study
Yoshiya Tanaka, Kahaku Emoto, Zhihong Cai, Takehiro Aoki, Douglas Schlichting, Terence Rooney and William Macias

The Journal of Rheumatology March 1 2016, 43 (3) 504-511; DOI: https://doi.org/10.3899/jrheum.150613

Main menu

User menu

Search

BARICITINIB

Content

Resources

Subscribers

More